BG
SUPN icon

BlackRock Group’s Supernus Pharmaceuticals SUPN Stock Holding History

BlackRock Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$2.13M Buy
84,363
+35,823
+74% +$800K ﹤0.01% 1728
2016
Q3 		$1.2M Buy
48,540
+14,842
+44% +$336K ﹤0.01% 1934
2016
Q2 		$687K Buy
33,698
+2,316
+7% +$41.1K ﹤0.01% 2141
2016
Q1 		$479K Sell
31,382
-3,460
-10% -$45.1K ﹤0.01% 2258
2015
Q4 		$469K Buy
34,842
+7,834
+29% +$121K ﹤0.01% 2225
2015
Q3 		$379K Sell
27,008
-6,988
-21% -$130K ﹤0.01% 2307
2015
Q2 		$577K Buy
+33,996
New +$484K ﹤0.01% 2216

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock Group's SUPN Position: Q4 2016 in Review

BlackRock Group increased its Supernus Pharmaceuticals (SUPN) stake by 74% in Q4 2016, buying an estimated $800K and bringing the position to 84,363 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1728.

BlackRock Group first reported a position in SUPN in Q2 2015 and has held it in 7 quarters since. 233 funds tracked by Wall St. Rank hold SUPN as of Q4 2016.

  • BlackRock Group held 84,363 shares of Supernus Pharmaceuticals worth $2.13M as of Q4 2016.
  • BlackRock Group bought 35,823 Supernus Pharmaceuticals shares in Q4 2016, an estimated $800K.
  • Supernus Pharmaceuticals made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1728 holding.
  • BlackRock Group first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 7 quarters since.
  • 233 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.